|
Cases, n
|
27
|
206
|
–
|
|
Age at surgery (years)
|
70.6 ± 6.3
|
72.5 ± 8.5
|
0.18
|
|
Sex (male/female, n)
|
5/22
|
32/174
|
0.58
|
|
BMI
|
22.8 ± 4.2
|
23.2 ± 3.7
|
0.59
|
|
BMD (T-score)
|
−1.900 ± 1.249
|
− 1.863 ± 0.924
|
0.93
|
|
Medications for PD
|
|
Dopamine precursors (yes/no)
|
23/4 (85.2%)
|
–
|
–
|
|
Dopamine agonists (yes/no)
|
8/19 (29.6%)
|
–
|
–
|
|
Monoamine oxidase type B inhibitors (yes/no)
|
6/21 (22.2%)
|
–
|
–
|
|
Other
|
4/23 (14.8%)
|
–
|
–
|
|
Medical comorbidities
|
|
Diabetes (yes/no)
|
1/26 (3.7%)
|
22/184 (10.7%)
|
0.49
|
|
Rheumatoid arthritis (yes/no)
|
0/27
|
9/197 (4.4%)
|
0.60
|
|
Renal dysfunction (yes/no)
|
0/27
|
19/187 (9.2%)
|
0.14
|
|
Cardiovascular disease (yes/no)
|
2/25 (7.4%)
|
26/180 (12.6%)
|
0.75
|
|
Cerebrovascular disease (yes/no)
|
5/22 (18.5%)
|
14/192 (6.8%)
|
0.053
|
|
Respiratory disease (yes/no)
|
0/27
|
21/185 (10.2%)
|
0.14
|
|
Follow-up duration (months)
|
50.3 ± 16.2
|
49.0 ± 14.1
|
0.68
|
|
Number of fixed levels
|
9.3 ± 2.6
|
7.8 ± 1.9
|
0.006
|
|
3CO (yes/no)
|
17/10
|
100/106
|
0.14
|
|
Etiology (post fracture/degenerative/previous lumbar fusion)
|
10/15/2
|
21/133/52
|
0.001
|
|
Fix to sacrum (yes/no)
|
22/5 (81.5%)
|
174/32 (84.1%)
|
0.78
|
|
Pre SVA (mm)
|
196.0 ± 63.7
|
135.4 ± 69.9
|
< 0.001
|
|
Pre LL (°)
|
2.1 ± 19.3
|
3.5 ± 20.5
|
0.75
|
|
Pre TLK (°)
|
18.1 ± 16.0
|
19.2 ± 17.0
|
0.28
|
|
Pre TK (°)
|
24.1 ± 15.4
|
27.4 ± 20.0
|
0.37
|
|
Pre SS (°)
|
17.1 ± 8.0
|
14.7 ± 11.4
|
0.34
|
|
Pre PT (°)
|
36.6 ± 8.6
|
34.5 ± 13.2
|
0.47
|
|
PI (°)
|
53.6 ± 9.6
|
49.8 ± 9.1
|
0.088
|
